Jin Il Han

Title: Innovations in Breast Cancer Prognosis by Jin Il Han

Introduction

Jin Il Han is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of medical technology, particularly in the area of breast cancer prognosis. With a total of 3 patents, his work focuses on improving the accuracy of cancer treatment predictions.

Latest Patents

One of his latest patents is a method for predicting the prognosis of breast cancer patients. This innovative method involves several steps, including obtaining a biological sample from the patient and measuring the mRNA expression levels of specific genes. The results can indicate whether a patient has a good or bad prognosis based on the expression levels of matrix metallopeptidase 11 (MMP11) and cluster of differentiation 2 (CD2). This method is particularly effective for predicting the prognosis of HER2-type breast cancer, which is known for its poor outcomes.

Another significant patent by Jin Il Han relates to predicting the effectiveness of chemotherapy in breast cancer patients. This method measures gene expression levels in biological samples to differentiate between patient groups with high and low chemotherapy effectiveness. The ability to accurately predict treatment outcomes can guide future breast cancer therapies.

Career Highlights

Jin Il Han is currently associated with Gencurix Inc., where he continues to develop innovative solutions for cancer treatment. His work has the potential to greatly enhance the quality of care for breast cancer patients.

Collaborations

He collaborates with esteemed colleagues, including Sang Rae Cho and Young Ho Moon, who contribute to the research and development efforts at Gencurix Inc.

Conclusion

Jin Il Han's contributions to breast cancer prognosis through his innovative patents demonstrate his commitment to improving patient outcomes. His work not only advances medical technology but also provides hope for better treatment strategies in the future.